Outcomes of patients lost to follow-up after antiretroviral therapy initiation in rural north-eastern South Africa

Julie Ambia¹, Chodziwadziwa Kabudula², Kathryn Risher¹, Francesc Xavier Gómez-Olive², Brian D. Rice³, David Etoori¹ and Georges Reniers¹,²

¹ Department of Population Health, London School of Hygiene & Tropical Medicine, London, UK
² MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
³ MeSH Consortium, Department of Public Health Environments and Society, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

Abstract

OBJECTIVE The vital status of patients lost to follow-up often remains unknown in antiretroviral therapy (ART) programmes in sub-Saharan Africa because medical records are no longer updated once the patient disengages from care. Thus, we aimed to assess the outcomes of patients lost to follow-up after ART initiation in north-eastern South Africa.

METHODS Using data from a rural area in north-eastern South Africa, we estimated the cumulative incidence of patient outcomes (i) after treatment initiation using clinical records, and (ii) after loss to follow-up (LTFU) using data from clients that have been individually linked to Agincourt Health and Demographic Surveillance System (AHDSS) database. Aside from LTFU, we considered mortality, re-engagement and migration out of the study site. Cox proportional hazards regression was used to identify covariates of these patient outcomes.

RESULTS Between April 2014 and July 2017, 3700 patients initiated ART and contributed a total of 6818 person-years of follow-up time. Three years after ART initiation, clinical record-based estimates of LTFU, mortality and documented transfers were 41.0% (95% CI: 38.5–43.4%), 1.9% (95% CI 1.0–3.2%) and 0.1% (95% CI 0.0–0.9%), respectively. Among those who were LTFU, the cumulative incidence of re-engagement, out-migration and mortality at 3 years were 38.1% (95% CI 33.1–43.0%), 49.4% (95% CI 43.1–55.3%) and 4.7% (95% CI 3.5–6.2%), respectively. Pregnant or breastfeeding women, foreigners and those who initiated ART most recently were at an increased risk of LTFU.

CONCLUSION LTFU among patients starting ART in north-eastern South Africa is relatively high and has increased in recent years as more asymptomatic patients have initiated treatment. Even though this tendency is of concern in light of the prevention of onwards transmission, we also found that re-engagement in care is common and mortality among persons LTFU relatively low.

keywords HIV/AIDS, loss to follow-up, re-engagement, competing risk analysis, record linkage, demographic surveillance system

Introduction

Sustained use of antiretroviral therapy (ART) among HIV-infected patients reduces HIV viral load to undetectable levels, slows the progression of HIV and reduces the risk of onwards sexual transmission [1, 2]. However, high rates of loss to follow-up (LTFU) have been reported in many HIV care and treatment programmes in sub-Saharan Africa [3–5]. Perception of good health, use of alternative medicine, stigma, treatment fatigue, lack of knowledge, transport fare and competing demands for time are some of the factors that are known to contribute to disengagement [6]. However, not all patients deemed LTFU have stopped taking ART, as some patients switch facilities [7, 8]. Thus it is important to better understand the vital and treatment status of the LTFU patients both for improving the delivery of HIV services and for estimating the impact of ART on HIV-associated mortality.

Several strategies have been employed to obtain information on the vital status of patients LTFU, including patient tracing, the review of obituaries in newspapers and record linkage with Civil Registration and Vital
African citizenship [16]. Former Mozambican refugees have now attained South Africa to ascertain both vital and migration status of patients who are LTFU. The link with the AHDS also allowed us to identify patients who are LTFU at one facility and subsequently registered at another facility that serves the AHDS population. We use these data to estimate outcomes of patients after (i) treatment initiation and (ii) LTFU.

Methods

Ethics statement

The study was approved by the University of the Witwatersrand Human Research Ethics Committee and the London School of Hygiene and Tropical Medicine Research Ethics Committee. Data analysis was conducted using anonymised data.

Study setting and population

The AHDS study area covers 475 km² in Bushbuckridge, Mpumalanga province, north-eastern South Africa. The AHDS has been tracking demographic and health events in people living in the HDSS boundary since 1992. As of 2014, the population was approximately 115 000 individuals living in 17 000 households spread across 31 villages [14]. Overall, 47.9% of the population are men and 52.1% are women [15]. One third of the population are former Mozambican refugees who moved into the area during the civil war that began in 1977 and ended in 1992. About 9 in 10 of the former Mozambican refugees have now attained South African citizenship [16].

A cross-sectional biomarker survey conducted in 2010–2011 estimated that one in five adults in the AHDS population were HIV-infected [17]. The likelihood of being diagnosed with HIV was higher among South Africans than foreigners [17]. HIV prevalence was higher among women (23.9%) than men (10.6%), consistent with other countries in sub-Saharan Africa (SSA) [18]. However, temporary labour migration is quite high among young adult men in the study site [19] and they may be under-represented in the AHDS serosurvey [20].

ART provision began in 2004 in two secondary hospitals, between 25 and 60 km away from the AHDS study area [13]. A community health centre, Bhubezi, was opened in 2007 in the AHDS study area and was the first to provide HIV care and treatment locally. Currently, HIV care and treatment services have been decentralised to 10 primary health care facilities in the AHDS study area (Figure 1). Initiation of ART among persons newly diagnosed with HIV at these facilities is in line with national antiretroviral therapy guidelines. Since December 2014, these recommended ART initiation to all pregnant or breastfeeding women and any patient with a CD4 count <500/µL [21]. In September 2016, the treatment eligibility criteria were further revised to include all persons diagnosed with HIV [22].

To promote adherence two non-governmental organisations conduct tracing of patients who disengage from care (Right to Care and Home-Based Carers (HBCs)) in the AHDS catchment area. To that end, nurses at the clinic prepare a list of patients LTFU and a Right to Care linkage officer contacts these patients by phone. If a patient cannot be traced by phone, the case is referred to HBCs for physical tracing.

Data

The core data infrastructure for this study consists of HIV patient records that are linked to the AHDS using Point-of-Contact Interactive Record Linkage (PIRL), a procedure that has been described elsewhere [23]. In brief, a field worker is stationed at the clinic reception area to inform all new patients about the study objectives and record linkage procedures. Patients who consent are asked to declare a number of personal identifiers that are used to search a local copy of the AHDS database using a probabilistic algorithm. Matches are confirmed in interaction with the patients, and the names of other household members are used as a key attribute to adjudicate between possible matches. The PIRL software tool also contains a provision to log follow-up visits [24].

Record linkage started in April 2014, at seven government facilities and in 2016 this was extended to include one additional health facility. In this study, we only included patients who had been linked before or at the time of ART initiation. From these eight health facilities, we extracted the following information from the clinic records; clinic visit dates, date of HIV diagnosis, date of ART initiation, baseline CD4 counts, WHO clinical staging, reason for ART initiation, pregnancy status, vital status (i.e. alive or dead from any cause), date of death and availability of a duly completed facility transfer form. The AHDS database contains information obtained from an annual household visits [13], including changes in residency and the vital status of all household members.
Operational definitions

A patient who had commenced ART was considered LTFU if they failed to return within 90 days of a scheduled appointment. Our analyses were conducted in two stages. The first set of analyses only make use of clinic attendance records, to prospectively follow patients from the date of ART initiation to either LTFU, a documented transfer, death or administrative censoring on the date of data extraction from clinical records (i.e. 15 July 2017). The second set of analyses make use of linked AHDSS and clinic attendance records to evaluate the outcomes of the patient who were deemed LTFU on the basis of their clinical record. In this second set of analyses, time was measured from the date of last clinic visit to the earliest of the following events: re-engagement, out-migration from the AHDSS, death or administrative censoring on the date of last AHDSS household visit.

An individual was considered to have migrated if he or she was reported in the AHDSS round to have permanently left the surveillance area. The date of migration is reported retrospectively by relatives and there may be some misreporting. Thus, all those who reported to have migrated just before their last clinic visit are here treated as if they migrated on the day of their last clinic visit. Re-engagement was defined as the resumption of clinic visits in the same clinic or another clinic within the AHDSS surveillance area. The latter is sometimes also referred to as ‘silent transfers’ [12]. The identification of silent transfers is facilitated through record linkage to the

Figure 1 Map of agincourt health and demographic surveillance system.
AHDSS. National origin was based on the country of father’s birth (i.e. South African or foreigner). Late presentation was a composite of CD4 counts of <250 cells/µL and WHO stage III or IV at time of ART initiation.

Data analysis

In our first set of analyses, we used competing risks survival analysis to estimate the cumulative incidence of (i) LTFU, (ii) all-cause mortality (as reported in clinic records only) and (iii) documented transfers following treatment initiation. The complement of these three probabilities represents the proportion of patients who were alive and still on ART in the same facility where they initiated treatment without interruptions in excess of 90 days following the last scheduled visit. For this analysis, we only use data from the clinic visit logs. To impute a return date, we added 30 days to all patients who never returned after initiating ART (as their clinic return dates were missing).

Our second set of analyses focuses on patients deemed LTFU, and relies on data from both clinic visit logs and the AHDSS. Again, we conduct competing risks survival analysis to estimate the cumulative incidence of (i) re-engagement, (ii) all-cause mortality and (iii) out-migration at or after LTFU. The complement of these three probabilities represents the proportion of patients that were LTFU but still alive, living in the study site and not known to be on treatment at another facility.

Covariates of the outcomes of interest are assessed using semi-parametric Cox regression models. Again, we first model LTFU after treatment initiation. Patients’ exposure time is ended at the time that they become LTFU, die or formally transfer out and right censored at the date of the clinic data extraction (15 July 2017). A similar approach is used for modelling the covariates of patient outcomes following LTFU. As stipulated above, we consider re-engagement with HIV care, out-migration from the study area and death as competing risks.

Covariates with P-value below 0.05 in bivariate analyses were included in the adjusted model. Schoenfeld residuals were used to evaluate the proportional hazards assumption (Figure S1–S4). Wherever the proportional hazards assumption was violated, we included a linear interaction between the covariate and analysis time. Data were analysed using Stata 14.0 (College Station, Texas, USA).

Results

Table 1 illustrates the characteristics of 3700 patients who were linked to an AHDSS record and initiated ART between 30 April 2014 and 15 July 2017. Majority of the patients (88.8%; 3700/4168) who reported residency in one of the AHDSS villages could be linked to an AHDSS record. The attributes of linked and unlinked records are further explored in a table in the supporting information (Table S1). All of these patients were reportedly ART naïve, but we cannot exclude that some previously received treatment elsewhere without declaring it as such. At the time of ART initiation less than a quarter of the patients were men and one-fifth of the patients were pregnant or breastfeeding. The median age at ART initiation was 38.7 years [Interquartile range (IQR): 31.9–46.0 years] among men, 34.3 years [IQR: 27.1–44.9 years] among non-pregnant women and 27.1 years [IQR: 23.4–31.6 years] among pregnant or breastfeeding women. Overall, 47.1% (1733/3681) of individuals presented late for care. The highest percentage of late presentation was observed among men (67%; 576/866), followed by non-pregnant women (46%; 950/2077), and pregnant or breastfeeding women (28%; 207/738). The 3700 patients jointly contributed a total of 6818 person-years of observation time to the analyses. Of the 966 patients LTFU, 3.8% were lost within 1 year of ART initiation, 25.9% within 2 years and 81.9% within 3 years.

Patient status after ART initiation

Figure 2 and Table S2 show the probabilities of patients being retained in care (n = 2704), dying (n = 28), LTFU (n = 966) or transferring (n = 4). Using exclusively clinic visit attendance records, the cumulative incidence of LTFU, mortality and documented transfers at 1 year after initiating ART were estimated at, 21.3% (95% CI 19.9–22.8%), 0.67% (95% CI 0.43–1.02%) and 0.13% (95% CI 0.04–0.86%), respectively. After 3 years, 41.0% (95% CI 38.5–43.4%) were LTFU, 1.88% (95% CI 1.03–3.17%) had died and 0.13% (95% CI 0.04–0.86%) were known to have transferred to another facility.

Patient status after LTFU

Figure 3 and Table S3 summarise the cumulative incidence of re-engagement (n = 267), out-migration (n = 298) and mortality (n = 44) after LTFU based on the linked clinic-AHDSS database. The cumulative incidence of re-engagement increased from 23.0% (95% CI 20.3–25.8%) at 1 year to 38.1% (95% CI 33.1–43.0%) at year 3. The cumulative incidence of out-migration increased from 22.8% (95% CI 20.1–25.5%) in year 1 to 49.4% (95% CI 43.1–55.3%) in year 3. About 15% who out-migrated at time 0 are those who had migrated between the date of last clinic visit and the date at which they are considered LTFU. The cumulative incidence of
mortality increased marginally from 4.5% (95% CI 3.3–6.0%) at year 1 to 4.7% (95% CI 3.5–6.2%) at year 3. The treatment status of the remaining 37% (357/966) could not be ascertained using the linked clinic-AHDSS dataset. After 3 years, about 10% of the patients were LTFU. These are patients who interrupted care at the place where they first initiated ART, are still living in the study area, and are not known to re-engaged at the same facility or transferred to another facility. The current treatment and vital status of patients who migrated out of the AHDSS area is also unknown.

Of the patients who resumed HIV care, 43.8% re-engaged in the same health facility, 53.9% continued treatment at another health facility and 2.2% continued care at two facilities in the AHDSS area. The cumulative incidence of transferring to another facility in the study site was 3.2% (95% CI 2.2–4.4%) at 1 year and 14.4% (95% CI 10.8–18.6%) at year 3.

Predictors of LTFU after ART initiation

Table 2 summarises the output of the regression model of LTFU following ART initiation. In both crude and
adjusted analysis, a linear interaction with time was added to the model whenever the proportional hazards assumption was violated. In many of these cases, the interaction term suggests that initial differences between patient subgroups decline as time goes on. Results of the tests for the proportional hazards assumption are presented in Table S4 and Figure S1 in the supporting information.

Pregnant or breastfeeding women had a more than twofold increased risk of LTFU (adjusted hazard ratio (AHR): $2.53; 95\% \text{ CI } 1.95–3.27$) compared with non-pregnant women, but their elevated risk of LTFU attenuated by 39% every year. Men’s risk of LTFU was initially not different from that of non-pregnant women, but increased by 27% each calendar year. Former Mozambican settlers had a 41% higher risk of LTFU (AHR: $1.41; 95\% \text{ CI } 1.13–1.75$) at time zero and it declined by 33% every year.

LTFU risks for persons under 50 years of age were initially comparable, but disparities increased over time with younger men and women experiencing higher LTFU risks at longer durations. Men and women who initiated ART in later calendar years (i.e. 2015, 2016 and 2017) were at a higher risk of LTFU, but the interactions with time all suggest that the differences decline as the time since starting ART increases.

**Predictors of re-engagement, mortality and out-migration after LTFU**

Table 3 summarises crude and adjusted hazard estimates of re-engagement, mortality and out-migration following LTFU from Cox regression models. The proportional hazards assumption was violated in two instances, and this was accommodated by the inclusion of a linear interaction between the covariate of interest and analysis time (Table S5 and Figures S2–S4). The interaction between age and analysis time on mortality is only included in the supporting information (Table S6) as it led to very large coefficient estimates due to quasi-separation in the data.

Initiating ART during pregnancy/breastfeeding (AHR: $0.61; 95\% \text{ CI } 0.44–0.84$) or being a foreigner (AHR $0.68; 95\% \text{ CI } 0.51–0.89$) were associated with a reduction in the risk of returning to care. Men and women who initiated ART in later calendar years (i.e. 2015 and 2016) were at a lower risk of returning to care, and the low risk intensified in the most recent period.

In univariate analysis, pregnant or breastfeeding women had a 73% lower hazard (HR $0.27; 95\% \text{ CI } 0.09–0.79$) of dying than non-pregnant women. After adjustment of other covariates, the relationship was no longer statistically significant. After adjustment, older age (≥50 years) was associated with an increase in mortality risk. The relative hazard of dying was higher among patients who presented late for ART initiation (AHR 3.34; 95\% CI 2.20–12.96) than in patients who presented early (WHO clinical stage I or II or with CD4 counts of >251 cells/μL).

In multivariate analysis, men (AHR: $0.65; 95\% \text{ CI } 0.48–0.90$) were at a lower risk of migrating out of AHDSS than women. Patients who initiated ART in later years (i.e. 2015 and 2016) were also more likely to migrate out of the study area than those who initiated in 2014.
Using data from eight clinics in north-eastern South Africa (Agincourt), we estimated that 21% and 41% of the patients were LTFU at 12 and 36 months after treatment initiation, respectively. The percentage of deaths and transfers to other facilities within 3 years that were recorded in the medical records were 2% and 0.1%, respectively. Our estimates of LTFU are higher than those in studies from Johannesburg (14% at 12 months) [25] and Tanzania (18% at 12 months) [26].

It is possible that LTFU rates have increased as a result of ART programmes expanding to include all persons newly diagnosed with HIV regardless of their CD4 cell count or clinical stage, thereby including a larger number of patients who initiate ART when they are still asymptomatic [27]. This also offers an explanation for the

| Table 3 Factors associated with re-engagement, mortality and out-migration following LTFU |
|---------------------------------|-----------|----------------|-----------|----------------|
|                                | Re-engagement | Mortality | Out-migration |
|                                | Crude HR (95% CI) | Adjusted HR* (95% CI) | Crude HR (95% CI) | Adjusted HR† (95% CI) | Crude HR (95% CI) | Adjusted HR‡ (95% CI) |
| **Sex & pregnancy status**     |            |            |            |            |            |            |
| Women (non-pregnant)           | 1          | 1          | 1          | 1          | 1          | 1          |
| Pregnant or breastfeeding women | 0.58 (0.43–0.79) | 0.61 (0.44–0.84) | 0.27 (0.09–0.79) | 0.69 (0.22–2.11) | 1.03          | 1.02 (0.79–1.32) |
| Men                            | 1.02 (0.77–1.35) | 1.03 (0.77–1.39) | 1.36 (0.73–2.53) | 0.85 (0.45–1.60) | 0.65          | 0.65 (0.48–0.90) |
| **National origin**            |            |            |            |            |            |            |
| South African                  | 1          | 1          | 1          | 1          | 1          | 1          |
| Foreigner                      | 0.69 (0.53–0.90) | 0.68 (0.51–0.89) | 1.32 (0.72–2.40) | 1.11 (0.88–1.40) |
| **Age at ART initiation**      |            |            |            |            |            |            |
| <20 years                      | 0.49 (0.28–0.86) | 0.58 (0.32–1.04) | 0.08 (0.02–0.33) | 0.12 (0.03–0.54) | 1.64 (0.86–3.13) |
| 20–29                          | 0.64 (0.40–1.01) | 0.77 (0.47–1.25) | 0.05 (0.02–0.16) | 0.08 (0.03–0.26) | 1.79 (0.99–3.23) |
| 30–39                          | 0.69 (0.43–1.11) | 0.77 (0.47–1.25) | 0.26 (0.12–0.55) | 0.28 (0.13–0.60) | 1.57 (0.86–2.89) |
| 40–49                          | 0.85 (0.51–1.41) | 0.84 (0.50–1.41) | 0.33 (0.14–0.73) | 0.33 (0.15–0.74) | 1.24 (0.64–2.41) |
| ≥50 years                      | 1          | 1          | 1          | 1          | 1          | 1          |
| **Year of ART initiation**     |            |            |            |            |            |            |
| 2014                            | 1          | 1          | 1          | 1          | 1          | 1          |
| 2015                            | 0.60 (0.37–0.96) | 0.56 (0.34–0.90) | 0.85 (0.44–1.65) | 1.09 (0.82–1.46) | 1.08 (0.81–1.44) |
| Time-varying                    | 1.75 (1.02–3.14) | 1.81 (1.01–3.26) | 1.51 (1.50–2.07) | 1.48 (1.07–2.04) |
| 2016                            | 0.22 (0.12–0.42) | 0.20 (0.10–0.39) | 0.48 (0.20–1.14) | 1.51 (1.09–2.07) | 1.48 (1.07–2.04) |
| Time-varying                    | 7.41 (3.11–17.71) | 8.47 (3.52–20.36) | 7.41 (3.11–17.71) | 8.47 (3.52–20.36) |
| **Late ART initiation**         |            |            |            |            |            |            |
| No                              | 1          | 1          | 1          | 1          | 1          | 1          |
| Yes                             | 1.28 (1.01–1.63) | 1.02 (0.79–1.33) | 7.86 (3.32–18.60) | 5.37 (2.21–13.04) | 0.91 (0.72–1.15) |

*Re-engagement: 
  No of subjects – 960
  No of failures – 265
  Time at risk – 852

†Mortality: 
  No of subjects – 960
  No of failures – 44
  Time at risk – 852

‡Out-migration: 
  No of subjects – 966
  No of failures – 298
  Time at risk – 856

Figures in bold showed statistical associations.

Discussion

Using data from eight clinics in north-eastern South Africa (Agincourt), we estimated that 21% and 41% of the patients were LTFU at 12 and 36 months after treatment initiation, respectively. The percentage of deaths and transfers to other facilities within 3 years that were recorded in the medical records were 2% and 0.1%, respectively. Our estimates of LTFU are higher than those in studies from Johannesburg (14% at 12 months) [25] and Tanzania (18% at 12 months) [26].

It is possible that LTFU rates have increased as a result of ART programmes expanding to include all persons newly diagnosed with HIV regardless of their CD4 cell count or clinical stage, thereby including a larger number of patients who initiate ART when they are still asymptomatic [27]. This also offers an explanation for the
higher LTFU rates among patients who initiated treatment in more recent calendar years.

Our finding that men and pregnant or breastfeeding women were at an increased risk of LTFU corroborates the results from other studies in sub-Saharan Africa [28–31]. For pregnant women in particular, it has been hypothesised that they are more likely to disengage from care because they are often asymptomatic and discontinue treatment once the risk of onwards transmission to her child has dissipated [32]. Women may also be more mobile to seek the support of her relatives around or after childbirth and that may also affect her health seeking behaviour.

Using linked clinic-HDSS data, we were in position to evaluate the outcomes of patients after they disengaged from ART services. Of the patients who were LTFU, 38% had re-engaged within 3 years, 49% migrated out of the HDSS area and 5% had died. Consistent with two systematic reviews of tracing studies [7, 33], death was the least important cause of LTFU in this cohort. It is also worth noting that mortality within 24 months of LTFU is lower than that reported in tracing studies in the Zambia where 8% had died within 2 years [34], and in East Africa where 13% had died within 3 years [8].

There are two possible explanations for these differences. On the one hand, these discrepancies with earlier tracing studies could be explained by declining mortality among patients LTFU over time. Even though our results do indeed point in that direction, they did not reach statistical significance by conventional standards. They are, however, plausible and could be attributed to a combination of factors including the availability of more effective ART regimens that are more forgiving of lapses in treatment and changes in ART initiation threshold guidelines, which mean patients increasingly initiate ART when they are still asymptomatic [22, 35, 36]. However, we cannot exclude that the disparities with earlier tracing studies are due to the fact that we could not establish the vital status of patient who had migrated out of the HDSS area. Even though migration is generally correlated with good health [37], this could be a source of bias in our estimates. Interestingly, men were less likely to have migrated than women, but we have no data to explore this association further.

We found that 14% of the patients had transferred to another facility at 36 months. Similar levels of transfers have been reported other African studies. In an individual patient data meta-analysis of nine tracing studies conducted in SSA, 15% of the patients had transferred to another facility at the third year [38]. A previous study cited the decentralisation of treatment and the proximity to new health facility offering ART as the main reason for transferring [11].

Study limitations
This study was done in one rural community in north-east South Africa, thus it may not be possible to generalise these findings. Second, ongoing studies such as the Nkateko health service trial in this area may have affected the study results. In brief, the main objective of this trial was to enhance adherence to clinic visits using phone-based reminders and home visits by lay health workers among patients with hypertension [39]. Of note, some of the hypertensive patients were also HIV-infected and thus benefited by being continually reminded of their clinic visits. Third, clinical data that was used in this study was obtained from patient attendance records and this restricted the variables that were available for analysis. Fourth, some patients may have been enrolled in differentiated care models that did not require them to visit clinics with the same frequency. Failing to account for these patients distinct visit patterns may have resulted to an overestimation of LTFU in this study. However, the rollout of differentiated care only started in late 2016, thus the number of patients enrolled in differentiated care model may have been negligible. Last, we did not quantify the quality of data linkage. A study in Tanzania that used a similar data linkage approach, managed to link 84% of the patients who declared residency in the HDSS area to an HDSS record [23].

Conclusion
As observed in clinical cohort studies in other African populations, LTFU among patients starting ART in north-eastern South Africa is relatively high. LTFU rates are typically higher among pregnant women but are also increasing in other patient subgroups as treatment eligibility criteria have expanded and patients increasingly start ART shortly after diagnosis when they are still asymptomatic. Whereas this tendency is of concern in light of the prevention of onwards transmission, we also found that re-engagement in care is common (40% within 3 years) and mortality relatively low (5% within 3 years). The LTFU and patient mobility rates identified in this population further suggest that surveillance methods that solely rely on clinic records without unique patient identifiers will be severely limited to accurately represent treatment coverage.

Acknowledgement
This study was supported by the Bill & Melinda Gates Foundation grants to the ALPHA Network [BMGF-OPP1082114] and the MeSH Consortium [BMGF-OPP1120138].
References

1. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis* 2011: 52: 793–800.

2. Colby DJ, Trautmann M, Pinyakorn S et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. *Nat Med* 2018: 24: 923–926.

3. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. *J Acquir Immune Defic Syndr* 2015: 69: 98–108.

4. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. *PLoS Med* 2007: 4: e298.

5. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. *Trop Med Int Health* 2010: 15(Suppl 1): 1–15.

6. Loeliger KB, Niccolai LM, Mtungwa LN, Moll A, Shenoi SV. Antiretroviral therapy initiation and adherence in rural South Africa: community health workers’ perspectives on barriers and facilitators. *AIDS Care* 2016: 28: 982–993.

7. Wilkinson LS, Skordis-Worrall J, Ajose O, Ford N. Self-transfer and mortality amongst adults lost to follow-up in ART programmes in low- and middle-income countries: systematic review and meta-analysis. *Trop Med Int Health* 2015: 20: 365–379.

8. Geng EH, Odeny TA, Lyamuya RE et al. Estimation of Mortality among HIV-infected people on antiretroviral therapy treatment in east Africa: a sampling based approach in an observational, multisite, cohort study. *Lancet HIV* 2015: 2: e107–e116.

9. Anglaret X, Toure S, Gourvellec G et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. *J Acquir Immune Defic Syndr* 2004: 35: 320–323.

10. Cornell M, Lessells R, Fox MP et al. Mortality among adults transferred and lost to follow-up from antiretroviral therapy programmes in South Africa: a multicenter cohort study. *J Acquir Immune Defic Syndr* 2014: 67: e67–e75.

11. Geng EH, Odeny TA, Lyamuya R et al. Retention in care and patient-reported reasons for undocumented transfer or stopping care among HIV-infected patients on antiretroviral therapy in Eastern Africa: application of a sampling-based approach. *Clin Infect Dis* 2016: 62: 935–944.

12. Geng EH, Gildan DV, Bwana MB et al. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. *PLOS ONE* 2011: 6: e21797.

13. Kahn K, Collinson MA, Gomez-Olive FX et al. Profile: agincourt health and socio-demographic surveillance system. *Int J Epidemiol* 2012: 41: 988–1001.

14. Kabudula CW, Houle B, Collinson MA, Kahn K, Tollman S, Clark S. Assessing changes in household socioeconomic status in rural South Africa, 2001–2013: a distributional analysis using household asset indicators. *Soc Indic Res* 2016: 00: 1–27.

15. Agincourt HDSS fact sheet 2014 [press release]; 2014.

16. Polzer T. Adapting to changing legal frameworks: mozambican refugees in South Africa. *Int J Refugee Law* 2007: 19: 22–50.

17. Gomez-Olive FX, Angotti N, Houle B et al. Prevalence of HIV among those 15 and older in rural South Africa. *AIDS Care* 2013: 25: 1122–1128.

18. UNAIDS. *Global AIDS Update* – 2016. UNAIDS: Geneva, Switzerland, 2016, 2016.

19. Tollman SM, Kahn K, Sartorius B, Collinson MA, Clark SJ, Garenne ML. Implications of mortality transition for primary health care in rural South Africa: a population-based surveillance study. *Lancet* 2008: 372: 893–901.

20. Camlin CS, Snow RC, Hosegood V. Gendered patterns of migration in rural South Africa. *Popul Space Place* 2014: 20: 528–551.

21. Meintjes G, Black J, Conradie F et al. Adult antiretroviral therapy guidelines 2014. *S Afr J HIV Med* 2014: 15: 121–143.

22. Pillay Y, Pillay A. Implementation of the Universal Test and Treat Strategy for HIV Positive Patients and Differentiated Care for Stable Patients. Department of Health: Pretoria, South Africa, 2016.

23. Rentsch C, Reniers G, Kabudula C et al. Point-of-contact interactive record linkage (PIRL) between demographic surveillance and health facility data in rural Tanzania. *Int J Populat Data Sci* 2017: 2: 3.

24. Reniers G, Wamukoya M, Urassa M et al. Data resource profile: network for analysing longitudinal population-based HIV/AIDS data on Africa (ALPHA Network). *Int J Epidemiol* 2016: 45: 83–93.

25. Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. *Trop Med Int Health* 2010: 15: 405–413.

26. Soni G, Keogh SC, Todd J et al. Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme. *Trop Med Int Health* 2012: 17: 497–506.

27. Grimsrud A, Balkan S, Casas EC et al. Outcomes of antiretroviral therapy over a 10-year period of expansion: a multicohort analysis of African and Asian HIV programs. *J Acquir Immune Defic Syndr* 2014: 67: e55–e66.

28. Giles ML, Achhra AC, Abraham AG et al. Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA). *J Int AIDS Soc* 2018: 21: e23149.

29. Aliyu MH, Blevins M, Megazzini KM et al. Pregnant women with HIV in rural Nigeria have higher rates of antiretroviral treatment initiation, but similar loss to follow-
up as non-pregnant women and men. *Int Health* 2015: 7: 405–411.

30. Boyles TH, Wilkinson LS, Leisegang R, Maartens G. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. *PLoS ONE* 2011: 6: e19201.

31. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. *AIDS* 2008: 22: 1679–1681.

32. Kim MH, Zhou A, Mazenga A et al. Why did i stop? Barriers and facilitators to uptake and adherence to ART in option B+ HIV care in Lilongwe, Malawi. *PLoS ONE* 2016: 11: e0149527.

33. Zurcher K, Mooser A, Anderegg N et al. Outcomes of HIV-positive patients lost to follow-up in African treatment programmes. *Trop Med Int Health* 2017: 22: 375–387.

34. Holmes CB, Sikazwe I, Sikombe K et al. Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: findings from a multi-stage sampling-based survey. *PLoS Med* 2018: 15: e1002489.

35. South Africa Department of Health. *South African Antiretroviral Treatment Guidelines 2013*. National Department of Health: South Africa, 2013.

36. Vermund SH. Massive benefits of antiretroviral therapy in Africa. *J Infect Dis* 2014: 209: 483–485.

37. Spallek J, Zech H, Razum O. What do we have to know from migrants’ past exposures to understand their health status? A life course approach. *Emerg Themes Epidemiol* 2011: 8: 6.

38. Chammartin F, Zürcher K, Keiser O et al. Outcomes of patients lost to follow-up in African antiretroviral therapy programs: individual patient data meta-analysis. *Clin Infect Dis* 2018: 67: 1643–1652.

39. Thorogood M, Goudge J, Bertram M et al. The Nkateko health service trial to improve hypertension management in rural South Africa: study protocol for a randomised controlled trial. *Trials* 2014: 15: 435.

### Supporting Information

Additional Supporting Information may be found in the online version of this article:

- Figure S1. Predicted hazards of LTFU and 95% CI.
- Figure S2. Predicted hazards of re-engagement and 95% CI.
- Figure S3. Predicted hazards of mortality and 95% CI.
- Figure S4. Predicted hazards of out-migration and 95% CI.
- Table S1. Characteristics of linked and unlinked patients initiating ART between April 2014 and July 2017 in the Agincourt sub-district in Mpumalanga Province, South Africa
- Table S2. Patient outcomes following ART initiation using clinic attendance records
- Table S3. Patient outcomes after LTFU ascertained through record linkage with the AHDSS
- Table S4. Patient outcomes following ART initiation proportional hazard assumption test
- Table S5. Patient outcomes after LTFU proportional hazard assumption test
- Table S6. Interaction between age and analysis time on mortality

### Corresponding Author

Julie Ambia, Department of Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK. E-mail: Julie.Ambia1@lshtm.ac.uk